Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada

Por Tang, P.A., Hay, A.E., O’Callaghan, C.J., Mittmann, N., Chambers, C.R., Pater, J.L., Leighl, N.B.
Publicado no Curr Oncol (2016)

Linkage of clinical trial and administrative data: a survey of cancer patient preferences

Por Hay, A.E., Leung, Y.W., Pater, J.L., Brown, M.C., Bell, E., Howell, D., Kassam, Z., Willing, S., Tian, C., Liu, G.
Publicado no Curr Oncol (2017)

Accrual of adolescents and young adults with cancer to clinical trials

Por Hay, A.E., Rae, C., Fraser, G.A., Meyer, R.M., Abbott, L.S., Bevan, S., McBride, M.L., Cuvelier, G.D.E., McKillop, S., Barr, R.D.
Publicado no Curr Oncol (2016)